John M. Climaco's most recent trade in Moleculin Biotech Inc was a trade of 10,000 Stock option (right to buy) done . Disclosure was reported to the exchange on Nov. 4, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Moleculin Biotech Inc | John M. Climaco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 10,000 | 15,169 | - | - | Stock option (right to buy) | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 83,000 | 559,533 | - | - | Restricted Stock Units | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 83,000 | 476,533 | - | - | Option to purchase common stock | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.30 per share. | 01 Feb 2024 | 166,666 | 215,676 (1%) | 1% | 0.3 | 50,000 | Common stock |
| Cns Pharmaceuticals Inc | M. John Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 166,666 | 226,867 | - | - | Series A Warrant to purchase common stock | |
| Cns Pharmaceuticals Inc | M. John Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 166,666 | 393,533 | - | - | Series B Warrant to purchase common stock | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.80 per share. | 16 Aug 2023 | 2,750 | 49,010 (0%) | 0% | 1.8 | 4,945 | Common Stock |
| Moleculin Biotech Inc | John M. Climaco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 77,501 | - | - | Stock option (right to buy) | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 1,250 | 60,201 | - | - | Restricted Stock Units | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 1,250 | 46,260 (0%) | 0% | - | Common Stock | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.69 per share. | 12 Apr 2023 | 15,000 | 45,010 (0%) | 0% | 0.7 | 10,409 | Common Stock |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 16,467 | 61,451 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | John M. Climaco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 23,333 | 47,501 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | John M. Climaco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 15,000 | 62,501 | - | - | Stock option (right to buy) | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 600,000 | 1,349,500 | - | - | Restricted Stock Units | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.28 per share. | 07 Mar 2022 | 35,000 | 940,298 (5%) | 0% | 0.3 | 9,835 | Common Stock |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 1.28 per share. | 16 Nov 2021 | 5,000 | 905,298 (5%) | 0% | 1.3 | 6,400 | Common Stock |
| Moleculin Biotech Inc | John M. Climaco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 24,168 | - | - | Stock option (right to buy) | |
| Cns Pharmaceuticals Inc | John M. Climaco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 310,000 | 749,500 | - | - | Option to purchase common stock (right to buy) |